利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

665 records (took 0.022 seconds)

    MODIFIED SECRETED HEPATITIS C VIRUS (HCV) E1E2 GLYCOPROTEINS AND METHODS OF USE THEREOF
    5.
    发明公开
    MODIFIED SECRETED HEPATITIS C VIRUS (HCV) E1E2 GLYCOPROTEINS AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：US20240016923A1

    公开(公告)日：2024-01-18

    申请号：US18252800

    申请日：2021-11-12

    Applicant: UNIVERSITY OF MARYLAND, COLLEGE PARK ,  THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

    Inventor： Brian G. Pierce ,  Thomas R. Fuerst ,  Eric A. Toth ,  Johnathan D. Guest ,  Steven K.H. Foung ,  Zhen-Yong Keck

    IPC: A61K39/29 ,  A61P31/14 ,  C07K14/18

    CPC classification number: A61K39/29 ,  A61P31/14 ,  C07K14/1833

    Abstract: Disclosed are modified hepatitis C virus (HCV) E1E2 glycoproteins. Disclosed are Disclosed are modified HCV E1E2 glycoproteins comprising a HCV E1 polypeptide; a first scaffold element; a HCV E2 polypeptide; and a second scaffold element, wherein the HCV E1 polypeptide does not comprise a transmembrane domain, and wherein the HCV E2 polypeptide does not comprise a transmembrane domain. Disclosed are modified HCV E1E2 glycoproteins comprising a HCV E1 polypeptide; a first scaffold element; a modified HCV E2 polypeptide; and a second scaffold element, wherein the HCV E1 polypeptide does not comprise a transmembrane domain; a first scaffold element, wherein the modified HCV E2 polypeptide does not comprise a transmembrane domain, wherein the modified HCV E2 polypeptide comprises an antigenic domain D, and wherein the modified HCV E2 polypeptide comprises one or more amino acid alterations in the antigenic domain D and/or wherein the modified HCV E2 polypeptide comprises an antigenic domain A, wherein the antigenic domain A comprises an N-glycan sequon substitution. Also disclosed are methods of using the disclosed modified HCV E1E2 glycoproteins, such as methods of inducing an immune response in a subject, methods of treating a subject, and methods of increasing antigenicity of a HCV E1E2 glycoprotein.

    Targeted mosquitocidal toxins
    8.
    发明授权
    Targeted mosquitocidal toxins 有权

    公开(公告)号：US11479583B2

    公开(公告)日：2022-10-25

    申请号：US15944285

    申请日：2018-04-03

    Applicant: BAYLOR UNIVERSITY

    Inventor： Christopher Michel Kearney ,  Grace Pruett

    IPC: C07K14/18 ,  C12N15/82 ,  C07K14/435 ,  C07K14/005 ,  A01N63/50

    Abstract: Insecticidal toxins described herein are fused toxin peptides made up of a targeting domain fused to a toxin domain. The targeting peptide generates a specific association with mosquitoes by causing the fused toxin peptide to bind mosquitoes in a way that leads to the insecticidal activity. Transgenic plants described herein are mosquitocidal by expressing an insecticidal toxin protein in nectar that includes a targeting peptide to ensure specificity against mosquitoes. These transgenic plants serve as role models for safety, since they are non-crop plants and specific to one mosquito species.

    Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes
    10.
    发明授权
    Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes 有权

    公开(公告)号：US11344614B2

    公开(公告)日：2022-05-31

    申请号：US16147637

    申请日：2018-09-29

    Applicant: Emergex Vaccines Holding Ltd.

    Inventor： Ramila Philip

    IPC: A61K39/12 ,  C07K14/18 ,  A61P31/14

    Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner. We show that epitope specific T cells can be activated in vivo in transgenic mice and in vitro in seropositive and seronegative individuals and that these T cells are functional, recognizing peptide pulsed and dengue virus infected cells in a pro-inflammatory and cytotoxic manner. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and may serve as a universal vaccine candidate complementary to current vaccines in trial.

Patent Agency Ranking